Evidence map›Paper›PMID 36300787›Full record

ArticleeLife2022

HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway.

Robert Krause, Jumari Snyman, Hwa Shi-Hsia, Daniel Muema, Farina Karim, Yashica Ganga, Abigail Ngoepe, Yenzekile Zungu, Inbal Gazy, Mallory Bernstein and 14 more

Abstract read
In one paragraph

Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The immune response to SARS-CoV-2 in people with HIV.Cellular & molecular immunology · 2024
    Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Robert KrauseAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0003-1558-0397
Jumari SnymanAfrica Health Research Institute, Durban, South Africa.
Hwa Shi-HsiaAfrica Health Research Institute, Durban, South Africa.
Daniel MuemaAfrica Health Research Institute, Durban, South Africa.
Farina KarimAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0001-9698-016X
Yashica GangaAfrica Health Research Institute, Durban, South Africa.
Abigail NgoepeAfrica Health Research Institute, Durban, South Africa.
Yenzekile ZunguAfrica Health Research Institute, Durban, South Africa.
Inbal GazySchool of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
Mallory BernsteinAfrica Health Research Institute, Durban, South Africa.
Khadija KhanAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0001-7565-7400
Matilda MazibukoAfrica Health Research Institute, Durban, South Africa.
Ntombifuthi MthabelaAfrica Health Research Institute, Durban, South Africa.
Dirhona RamjitAfrica Health Research Institute, Durban, South Africa.
COMMIT-KZN Team
Oliver LimboInternational AIDS Vaccine Initiative, New York, United States.
Joseph JardineInternational AIDS Vaccine Initiative, New York, United States.
Devin SokInternational AIDS Vaccine Initiative, New York, United States.
Ian A WilsonThe Scripps Research Institute, La Jolla, United States.
Willem HanekomAfrica Health Research Institute, Durban, South Africa.
Alex SigalAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0001-8571-2004
Henrik KløverprisAfrica Health Research Institute, Durban, South Africa.
Thumbi Ndung'uAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0003-2962-3992
Alasdair LeslieAfrica Health Research Institute, Durban, South Africa.

Funding

Wellcome TrustWellcome Trust 201433/Z/16/Z
6 · The paper itself

Abstract

Background: HIV infection dysregulates the B cell compartment, affecting memory B cell formation and the antibody response to infection and vaccination. Understanding the B cell response to SARS-CoV-2 in people living with HIV (PLWH) may explain the increased morbidity, reduced vaccine efficacy, reduced clearance, and intra-host evolution of SARS-CoV-2 observed in some HIV-1 coinfections. Methods: We compared B cell responses to COVID-19 in PLWH and HIV negative (HIV-ve) patients in a cohort recruited in Durban, South Africa, during the first pandemic wave in July 2020 using detailed flow cytometry phenotyping of longitudinal samples with markers of B cell maturation, homing, and regulatory features. Results: This revealed a coordinated B cell response to COVID-19 that differed significantly between HIV-ve and PLWH. Memory B cells in PLWH displayed evidence of reduced germinal centre (GC) activity, homing capacity, and class-switching responses, with increased PD-L1 expression, and decreased Tfh frequency. This was mirrored by increased extrafollicular (EF) activity, with dynamic changes in activated double negative (DN2) and activated naïve B cells, which correlated with anti-RBD-titres in these individuals. An elevated SARS-CoV-2-specific EF response in PLWH was confirmed using viral spike and RBD bait proteins. Conclusions: Despite similar disease severity, these trends were highest in participants with uncontrolled HIV, implicating HIV in driving these changes. EF B cell responses are rapid but give rise to lower affinity antibodies, less durable long-term memory, and reduced capacity to adapt to new variants. Further work is needed to determine the long-term effects of HIV on SARS-CoV-2 immunity, particularly as new variants emerge. Funding: This work was supported by a grant from the Wellcome Trust to the Africa Health Research Institute (Wellcome Trust Strategic Core Award [grant number 201433/Z/16/Z]). Additional funding was received from the South African Department of Science and Innovation through the National Research Foundation (South African Research Chairs Initiative [grant number 64809]), and the Victor Daitz Foundation.

Indexed as

COVID-19HIV InfectionsAntibodies, ViralHumansSARS-CoV-2South AfricaSpike Glycoprotein, CoronavirusAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2B cellCOVID-19epidemiologyglobal healthHIVhumanimmunologyinflammationRBDSARS-CoV-2spike

Identifiers

PMID36300787
PMCPMC9643005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.